Data tells me no safety issues, with a possible large therapeutic window.

Then they dropped the “good” totally “not disappointing” data that Remi was so “Thrilled” about.

This will go beyond parabolic on good data … literally no shares out there unless they offer new ones … $MDGL $VKTX $SLS $SAVA

SAVA data gets analyzed by multiple different labs and shows its cognition improvement in mild AD cases, safe and well-tolerated

$SAVA I love not being able to hold $28 off data that will keep it pinned here until 2024.

but the data to date would predict continued efficacy that will be nigh on impossible to ignore.

Data teasing is very positive. 🚀

$SAVA Institutional buying says data is good!! !

I’ll keep buying until data comes out…

Excited for the next data unveiling….bring it on!

T-13 average weekly TRx data has reached a new all-time high for 9 weeks in a row.

$AUPH Thanks for the data, nice growth again on a 2-week basis: wk TRx NRx TRx % change 2 52 14 4 57 20 +10% 6 62 24 +9% 8 67 20 +8% 10 73 24 +9%

T-13 average weekly TRx data has reached a new all-time high for 8 weeks in a row.

T-13 average weekly TRx data has reached a new all-time high for 7 weeks in a row.

Thank you so much to share below data with us 🙏

Therefore, we can conclude that the A2 data readouts were truly excellent!

Data and now approved in Europe… I remain bullish… shake out ! !

$GLTO amazing data, should run to $4-$5 once the algo's kick in after the 8am call $NXTC $KZR $AUPH

PROC data are excellent compared to any combo trials.

The cash should last them till after GFH-009 P2 data and REGAL P3 data.

Very Exciting - management has seen the GFH OS / and Cr data that is measured in weeks.

Hugely valuable when GFH Final Data comes in w a 30% plus CR rate for r/r AML 3 previous lines $MRK $bmy deals in play - Next Week

But yesterdays paper also has me considering, if there isn't a deal with $mrk or $BMY or some other CPI BP --- That data is Best In Class - best in clinic, best in trial too.

This will go beyond parabolic on good data … literally no shares out there unless they offer new ones … $MDGL $VKTX $SLS $SAVA

Early data were amazing could easily do MDGL

$MRK Ovarian cancer data final P2 results are better than any other drugs by a mile.

but positive news on the data side & you can see the mass accumulation cycle highlighted in green.

Gps + Opdivo $bmy Meso data due now will be better than all other treatments.